On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Stocks To Buy Now


Brain Scientific Inc. (BRSF) Offers Stock to Wider Pool of Investors Through Dalmore Group

  • BRSF announce partnership with Dalmore Group
  • New product launch presents solution for growing need for rapid EEG testing due to COVID-19 pandemic
  • Brain Scientific shose to extend proposed Reg A+ offering to attract additional investors

Brain Scientific (BRSF), a commercial-stage healthcare company providing next-gen solutions to the neurology market, has announced a partnership with the Dalmore Group in a recent press release (https://ibn.fm/clcDx).

“We are delighted to get the Dalmore Group on board and to be able to offer our stock to a much wider pool of investors,” said Brain Scientific chairman Boris Goldstein. “Our partners are experienced with Regulation A+ offerings and are licensed in all 50 states.”

The Dalmore Group is a member of FINRA and SIPC with an active presence in the Regulation A+ equity funding space. As one of the most active broker-dealers in the world, the company has served as broker-dealer on more than 50 RegA+ offerings in the past 12 months alone. In 2019 the Dalmore Group raised over $1 billion of capital. The majority of Dalmore Group’s clients come by referral from securities attorneys and industry participants.

BRSF is looking to the Dalmore Group for its expert strategic advice and innovative solutions. The Dalmore Group prides itself on understanding a client’s critical business processes and financial goals in order to provide the most comprehensive services possible.

Brain Scientific recently launched the next-gen, 19-channel NeuroCap(TM) device. This is a hospitable-grade disposable EEG headset that presents a solution for the growing need for rapid EEG testing due to the COVID-19 pandemic. Through the use of a special adapter, the NeuroCap is compatible with any other amplifiers of EEG signals.

Two of the biggest challenges of administering EEGs is the need to measure a patient’s head and the time needed to place the electrodes accurately. This required a specialized neurological technician. The pre-gelled fixed electrode locations, in accordance with the International 10-20 System, allow the NeuroCap to be administered by any healthcare worker making it more accessible to a larger group of patients.

The ease of use opens the device up for application in hospitals, clinics and rural areas where medical resources may be limited. Also, the global pandemic is still raging, and new studies show more than 80% of hospitalized COVID-19 patients have neurological symptoms, which could require EEG testing (https://ibn.fm/qRf8w).

“With our recent product development and new product launches,” said Goldstein, “we feel the need to extend the proposed Regulation A+ Offering to attract additional investors, which we believe we can better accomplish by working with Dalmore.”

For more information, visit the company’s website at www.BrainScientific.com.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

From Our Blog

MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) Obtains Patent for Mustard-Derived Fumigation of Stored Vegetables, Grains

December 4, 2020

Alternatives to potato sprout inhibition in critical need as U.S. moves towards eliminating CIPC CIPC, leading agrochemical product used for sprout suppression, was banned by EU in October MGRO’s patent focused on controlling vegetable, potato sprouting without harmful synthetic chemicals MustGrow Biologics (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) has been granted an exclusive patent licensing […]

Rotate your device 90° to view site.